Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People whose ability to carry out daily activities is rated at a high level (ECOG performance status of 0 or 1, meaning fully active or restricted only in physically strenuous activity)
• People who have been diagnosed with pancreatic ductal adenocarcinoma that has spread to other parts of the body, confirmed through tissue or cell testing
• People whose cancer has spread (metastatic disease)
• People who have not yet received any systemic (whole-body) treatment for their pancreatic cancer
• People whose cancer can be measured on scans according to standard criteria (RECIST 1.1)
• People whose heart, liver, kidneys, and bone marrow are functioning at levels that meet the study's requirements
• Women who could become pregnant must have a negative blood pregnancy test before joining
• Both men and women must agree to use an acceptable form of contraception for the duration of the study
• People who are able to understand what the study involves, including its requirements, risks, and discomforts, and are willing to sign a consent form

Who may not be able to join:

• People who have received chemotherapy for pancreatic cancer, or any chemotherapy for another cancer within the past 5 years
• People who have had radiation therapy for pancreatic cancer
• People who have taken part in another clinical trial or used an experimental device within the 28 days before the study starts
• People who have had major surgery (other than a biopsy or an incomplete Whipple procedure) within the 28 days before the study starts
• People who are expected to need other cancer treatments while on the study
• People who have previously received certain types of immunotherapy drugs (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies)
• People who have received a live or live-attenuated vaccine within 28 days before the first study treatment
• People who have ever received a transplanted tissue or organ from another person, including a cornea transplant
• People who have uncontrolled ongoing or long-term illness
• People who have a history of cancer spreading to the brain or the lining around the brain or spinal cord
• People who have another cancer that is currently growing and requires active treatment
• People with an active autoimmune disease (where the immune system attacks the body's own tissues)
• People who have been diagnosed with an immune system deficiency, or who are taking steroid medications at a dose higher than 10 mg of prednisone (or equivalent) per day on an ongoing basis
• People with any condition, treatment history, or abnormal test result that the treating doctor believes would interfere with the study results or would not be in the person's best interest
• People who require supplemental oxygen every day
• People with a history of certain lung conditions, including interstitial lung disease, non-infectious lung inflammation, pulmonary fibrosis, acute lung disease, COPD, or asthma requiring medication
• People with a known history of HIV
• People with active or chronic hepatitis B or hepatitis C
• People who are unable to have blood drawn through a vein
• People with a known psychiatric condition or substance use disorder that would make it difficult to follow the study requirements
• People who are pregnant or breastfeeding
• Women who could become pregnant and have a positive urine pregnancy test within 72 hours before starting the study treatment

Important: Always verify eligibility with the trial site directly before applying.